By: Patricia Van Arnum, DCAT Editorial Director
Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare, and animal health. But with such a large play into crop protection, where does its pharmaceuticals business now stand?
With the acquisition, Bayer’s crop-science business will now be the largest piece of Bayer by revenue, eclipsing its pharmaceutical business, which accounted for nearly 50% of the company’s sales in 2017.
DCAT Value Chain Insights
examines the new Bayer.